A549 |
Cell Viability Assay |
50 μM |
24Â h |
|
inhibits MMS-induced cell death |
26472723 |
MEFs |
Cell Viability Assay |
10âμM |
48 h |
DMSO |
inhibits zVAD-promoted death of CNOT3-depleted MEFs |
26437789 |
BMDM |
Function Assay |
10 μM |
30Â min |
|
protects cells from TAKI-induced LDH release |
26381601 |
NCI-H28 |
Cell Viability Assay |
10 μM |
24Â h |
|
prevents DAPE-induced reduction of NCI-H28 cell viability |
26004138 |
MiaPaCa-2 |
Function Assay |
20 μM |
24 h |
|
decreases the early necrotic cells |
26000607 |
BxPC-3 |
Function Assay |
20 μM |
24 h |
|
decreases the early necrotic cells |
26000607 |
SGC-7901 |
Cell Viability Assay |
30 μM |
1Â h |
|
suppresses oxaliplatin-mediated cell death |
25767076 |
KMS-12-PE |
Cell Viability Assay |
60 μM |
5 h |
|
inhibits SHK-induced cell death |
25530098 |
L929-A |
Cell Viability Assay |
50 μM |
24 h |
|
blocks TNFα-induced cell death |
25398540 |
L929-N |
Cell Viability Assay |
50 μM |
24 h |
|
blocks TNFα-induced cell death |
25398540 |
L929-A |
Function Assay |
50 μM |
12 h |
|
blocks the cleavage of Caspase-3 and PARP |
25398540 |
L929-N |
Function Assay |
50 μM |
12 h |
|
blocks the cleavage of Caspase-3 and PARP |
25398540 |
L929 |
Function Assay |
50 μM |
12 h |
|
inhibits TNFα-induced Bid cleavage |
25398540 |
L929-A |
Function Assay |
50 μM |
12 h |
|
inhibits the TNFα-induced loss of mitochondrial membrane permeability |
25398540 |
L929 |
Cell Viability Assay |
30 μM |
1Â h |
|
inhibits TNF-α-induced loss of cell viability |
25095742 |
L929 |
Cell Viability Assay |
30 μM |
1Â h |
|
inhibits TNF-α-induced cleavage of Topo I |
25095742 |
Huh7 |
Cell Viability Assay |
50 µM |
24/48 h |
DMSO |
prevents cell death of rAdHCV co-infected Huh7 cells |
24973240 |
OHC |
Function Assay |
300âμM |
|
DMSO |
increases noise-induced condensed nuclei |
24874734 |
OHC |
Function Assay |
300âμM |
|
DMSO |
decreases noise-induced swollen nuclei |
24874734 |
OHC |
Function Assay |
300âμM |
|
DMSO |
results in a reduction of noise-induced RIP1 and RIP3 immunofluorescence |
24874734 |
OHC |
Function Assay |
300âμM |
|
DMSO |
diminishes noise-induced AMPK activation |
24874734 |
OHC |
Function Assay |
300âμM |
|
DMSO |
increases the number of apoptotic OHCs without altering the levels of CC8 after noise exposure |
24874734 |
SK-Hep1 |
Function Assay |
60âμM |
18âh |
|
blocks β-lapachone-induced morphological change, cell death and PI uptake |
24832602 |
SK-Hep1 |
Function Assay |
60âμM |
18âh |
|
inhibits β-Lapachone-induced leakage of HMGB-1 |
24832602 |
SK-Hep1 |
Function Assay |
60âμM |
18âh |
|
blocks β-lapachone-mediated PAR accumulation and AIF translocation to the cytosol |
24832602 |
L-540 |
Function Assay |
60âμm |
1âh |
|
prevents the generation of ROS |
24561519 |
L-540 |
Function Assay |
60âμm |
1âh |
|
prevents the mitochondrial membrane depolarization |
24561519 |
L-540 |
Cell Viability Assay |
60âμm |
1âh |
|
reduces the Givinostat/Sorafenib-induced cell death |
24561519 |
AGS |
Cell Viability Assay |
60âμm |
1âh |
|
prevents shikonin-induced cell death |
24463199 |
NRK-52E |
Cell Viability Assay |
20 μM |
24 h |
|
protects cells from cell death caused by ischemia injury |
24351845 |
NRK-52E |
Cell Viability Assay |
20 μM |
24 h |
|
increases cell viability after TNF-α Stimulation and ATP Depletion |
24351845 |
NRK-52E |
Cell Viability Assay |
20 μM |
24 h |
|
inhibits increased Drp1 protein expression after TNF-α Stimulation and ATP Depletion |
24351845 |
L929 |
Function Assay |
2/5 μg/ml |
24Â h |
|
reversed the autophagy induced by TNFα alone as well as TNFα + zVAD |
23941769 |
L929 |
Growth Inhibition Assay |
2/5 μg/ml |
24Â h |
|
reverses the cell growth inhibition and cell death induced by TNFα alone as well as TNFα + zVAD |
23941769 |
L929 |
Function Assay |
2 μg/ml |
24Â h |
|
promots caspase-6 (p20) activity and procaspase-6 cleavage |
23941769 |
L929 |
Function Assay |
5 μg/ml |
24Â h |
|
blocks zVAD induced necroptosis and autophagy |
23941769 |
C6 |
Cell Viability Assay |
1 mmol/L |
3 h |
|
attenuates Shikonin induced glioma cell death |
23840441 |
U87 |
Cell Viability Assay |
1 mmol/L |
3 h |
|
attenuates Shikonin induced glioma cell death |
23840441 |
C6 |
Cytotoxicity Assay |
1 mmol/L |
3 h |
|
blocks shikonin induced necrosis |
23840441 |
U87 |
Cytotoxicity Assay |
1 mmol/L |
3 h |
|
blocks shikonin induced necrosis |
23840441 |
C6 |
Function Assay |
1 mmol/L |
1.5-3 h |
|
suppresses the expression of RIP-1 caused by shikonin |
23840441 |
U87 |
Function Assay |
1 mmol/L |
1.5-3 h |
|
suppresses the expression of RIP-1 caused by shikonin |
23840441 |
TE671 |
Cell Viability Assay |
40âμg/ml |
24 h |
|
rescues GX15-070-induced loss of cell viability |
23744296 |
RMS13 |
Cell Viability Assay |
40âμg/ml |
24 h |
|
rescues GX15-070-induced loss of cell viability |
23744296 |
MEFs |
Cytotoxicity Assay |
2/6/20 μM |
18 h |
|
inhibits TNFα-induced cell death in RelA KO MEFs |
23727581 |
MEFs |
Function Assay |
20 μM |
1/2/4 h |
|
suppresses TNFα-induced RIPK1 phosphorylation |
23727581 |
ΔN-Karpas 299 |
Cytotoxicity Assay |
20 μM |
16 h |
|
inhibits CD30-induced cell death |
23545938 |
MM.1S |
Cytotoxicity Assay |
90 µM |
1 h |
|
blocks BAY 11-7082 induced rapid cell swelling |
23527154 |
KMS-12-BM |
Cytotoxicity Assay |
90 µM |
1 h |
|
blocks BAY 11-7082 induced rapid cell swelling |
23527154 |
HT-22 |
Cell Viability Assay |
10 μM |
12Â h |
DMSO |
protects against glutamate-induced cell death |
23307752 |
HT-22 |
Function Assay |
25 μM |
0â30Â min |
DMSO |
inhibits ERK Activation induced by glutamate |
23307752 |
NIH3T3 |
Function Assay |
10/50 μM |
1/3 h |
|
ameliorates TNFα-driven complex formation |
23261677 |
SH-EP |
Apoptosis Assay |
10âμM |
72âh |
|
inhibits IAP inhibitor- and Lexatumumab-induced apoptosis |
22890322 |
HL60 |
Apoptosis Assay |
60 μM |
12 h |
|
enhances shikonin-induced apoptosis |
22837689 |
HL60/Adr |
Apoptosis Assay |
60 μM |
12 h |
|
enhances shikonin-induced apoptosis |
22837689 |
K562 |
Apoptosis Assay |
60 μM |
12 h |
|
enhances shikonin-induced apoptosis |
22837689 |
K562/Adr |
Apoptosis Assay |
60 μM |
12 h |
|
enhances shikonin-induced apoptosis |
22837689 |
HL60 |
Function Assay |
60 μM |
12 h |
|
augments the caspase-3 activity |
22837689 |
HL60/Adr |
Function Assay |
60 μM |
12 h |
|
augments the caspase-3 activity |
22837689 |
K562 |
Function Assay |
60 μM |
12 h |
|
augments the caspase-3 activity |
22837689 |
K562/Adr |
Function Assay |
60 μM |
12 h |
|
augments the caspase-3 activity |
22837689 |
HL60 |
Function Assay |
60 μM |
12 h |
|
increases the activity of caspases, caspase 8 and 9 |
22837689 |
HL60/Adr |
Function Assay |
60 μM |
12 h |
|
increases the activity of caspases, caspase 8 and 9 |
22837689 |
K562 |
Function Assay |
60 μM |
12 h |
|
increases the activity of caspases, caspase 8 and 9 |
22837689 |
K562/Adr |
Function Assay |
60 μM |
12 h |
|
increases the activity of caspases, caspase 8 and 9 |
22837689 |
L929sA |
Apoptosis Assay |
10 μM |
1 h |
|
inhibits the apoptotic response to TNF |
22362767 |
L929sA |
Apoptosis Assay |
10 μM |
1 h |
|
rescues cells expressing RIPK1ÎID from TNF-induced apoptosis |
22362767 |
L929sA |
Apoptosis Assay |
10 μM |
1 h |
|
abrogates the interaction of caspase-8 with FADD |
22362767 |
TPC-1 |
Cell Viability Assay |
100 μM |
24 h |
DMSO |
increases cellular survival |
22136818 |
8505c |
Cell Viability Assay |
100 μM |
24 h |
DMSO |
increases cellular survival |
22136818 |
SW13 |
Cell Viability Assay |
100 μM |
24 h |
DMSO |
increases cellular survival |
22136818 |
Jurkat |
Cytotoxicity Assay |
50/ 100/200 μm |
1/3 h |
|
reduces Naegleria fowleri-induced cytotoxicity |
21535020 |
Jurkat |
Function Assay |
200 μm |
30 min |
|
reduces Naegleria fowleri-induced reactive oxygen species (ROS) generation |
21535020 |
HT-22 |
Cytotoxicity Assay |
10 μM |
12 h |
|
protects against cell death induced by 5 mmol/L glutamate |
17760869 |